Safety and Efficacy of Neoadjuvant Chemoimmunotherapy in Gastric Cancer Patients with a PD-L1 Positive Status: A Case Report

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2023 Sep 27

PMID 37754265

Authors

Alexandra V Avgustinovich

Olga V Bakina

Sergey G Afanasev

Liudmila V Spirina

Alexander M Volkov

Affiliations

Soon will be listed here.

Abstract

Introduction: The landscape of gastric cancer treatment has changed owing to the widespread use of immune checkpoint inhibitors. Autophagy, involved in regulating the immune system, is a potential trigger of immunity in tumors. This study aims to find molecular-based evidence for the effectiveness of FLOT chemotherapy with immune checkpoint inhibitors in gastric cancer patients.

Materials And Methods: Three patients with advanced gastric cancer received FLOT neoadjuvant chemotherapy with immunotherapy and surgery. IHC was used to determine the PD-L1 status. Real-time PCR was used to analyze expression patterns of transcriptional growth factors, AKT/mTOR signaling components, PD-1, PD-L1, PD-L2 and LC3B. The LC3B content was measured via Western blotting analysis.

Results: The combination of FLOT neoadjuvant chemotherapy and immunotherapy was found to be efficient in patients with a PD-L1-positive status. Gastric tumors with a PD-L1-positive status exhibited autophagy activation and decreased PD-1 expression.

Conclusions: FLOT chemotherapy combined with immune checkpoint inhibitors showed high efficacy in gastric cancer patients with a positive PD-L1 status. Autophagy was involved in activating the tumor immunity. Further research is needed to clarify the mechanism of effective anticancer treatment.

Citing Articles

Case report: Nutritionally supported perioperative chemo-immunotherapy for advanced gastric cancer with incomplete pyloric obstruction.

Jian M, Yang Z, Hu X, Wang X, Zhang Z, Zhang Y Front Oncol. 2024; 14:1383076.

PMID: 38715783 PMC: 11074354. DOI: 10.3389/fonc.2024.1383076.

References

Li S, Yu W, Xie F, Luo H, Liu Z, Lv W . Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023; 14(1):8. PMC: 9810618. DOI: 10.1038/s41467-022-35431-x. View

Bang Y, Van Cutsem E, Fuchs C, Ohtsu A, Tabernero J, Ilson D . KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019; 15(9):943-952. DOI: 10.2217/fon-2018-0581. View

Chida K, Kawazoe A, Kawazu M, Suzuki T, Nakamura Y, Nakatsura T . A Low Tumor Mutational Burden and Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clin Cancer Res. 2021; 27(13):3714-3724. DOI: 10.1158/1078-0432.CCR-21-0401. View

Wang X, Wu W, Gao J, Li Z, Dong B, Lin X . Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res. 2019; 38(1):140. PMC: 6440013. DOI: 10.1186/s13046-019-1148-5. View

Sun L, Wang Q, Chen B, Zhao Y, Shen B, Wang H . Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell Death Dis. 2018; 9(9):928. PMC: 6134105. DOI: 10.1038/s41419-018-0988-9. View

Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J . Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. PLoS One. 2016; 11(3):e0152448. PMC: 4816386. DOI: 10.1371/journal.pone.0152448. View

He Q, Chen J, Zhou K, Jin C, Wang A, Ji K . Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer. Ann Surg Oncol. 2021; 28(8):4413-4422. DOI: 10.1245/s10434-020-09405-6. View

Lee D, Choi J, Oh H, Ham I, Lee S, Nomura S . Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer. Cancer Res Treat. 2022; 55(1):167-178. PMC: 9873335. DOI: 10.4143/crt.2022.094. View

Wu L, Cai S, Deng Y, Zhang Z, Zhou X, Su Y . PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression. Int Immunopharmacol. 2021; 94:107443. DOI: 10.1016/j.intimp.2021.107443. View

10.

Wang Z, Wang X, Xu Y, Li J, Zhang X, Peng Z . Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Med. 2022; 20(1):133. PMC: 9022268. DOI: 10.1186/s12916-022-02327-y. View

11.

Lin X, Zhao Y, Song W, Zhang B . Molecular classification and prediction in gastric cancer. Comput Struct Biotechnol J. 2015; 13:448-58. PMC: 4556804. DOI: 10.1016/j.csbj.2015.08.001. View

12.

Fuchs C, Doi T, Jang R, Muro K, Satoh T, Machado M . Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018; 4(5):e180013. PMC: 5885175. DOI: 10.1001/jamaoncol.2018.0013. View

13.

Sah B, Zhang B, Zhang H, Li J, Yuan F, Ma T . Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020; 11(1):6093. PMC: 7705676. DOI: 10.1038/s41467-020-19965-6. View

14.

Spirina L, Avgustinovich A, Bakina O, Afanasev S, Volkov M, Kebekbayeva A . LC3B, mTOR, AMPK Are Molecular Targets for Neoadjuvant Chemotherapy in Gastric Cancers. Curr Issues Mol Biol. 2022; 44(7):2772-2782. PMC: 9315670. DOI: 10.3390/cimb44070190. View

15.

Sinha D, Moseley P, Lu X, Wright Q, Gabrielli B, Frazer I . Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. Cancers (Basel). 2022; 14(24). PMC: 9776741. DOI: 10.3390/cancers14246150. View

16.

Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T . PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017; 8(38):64066-64082. PMC: 5609984. DOI: 10.18632/oncotarget.19318. View

17.

Guo H, Tang H, Zhao Y, Zhao Q, Hou X, Ren L . Molecular Typing of Gastric Cancer Based on Invasion-Related Genes and Prognosis-Related Features. Front Oncol. 2022; 12:848163. PMC: 9203697. DOI: 10.3389/fonc.2022.848163. View

18.

Kang Y, Chen L, Ryu M, Oh D, Oh S, Chung H . Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind,.... Lancet Oncol. 2022; 23(2):234-247. DOI: 10.1016/S1470-2045(21)00692-6. View

19.

Spirina L, Avgustinovich A, Afanasev S, Volkov M, Dobrodeev A, Cheremisina O . PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation. Int J Mol Sci. 2021; 22(20). PMC: 8539424. DOI: 10.3390/ijms222011176. View

20.

Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51(2):202-206. PMC: 6365097. DOI: 10.1038/s41588-018-0312-8. View